Tesamorelin: The Only FDA-Approved Growth Hormone Secretagogue
An evidence-checked research brief reviewing the NEJM pivotal trial for tesamorelin, the only growth hormone-releasing factor to complete a full FDA regulatory pathway, approved for HIV-associated lipodystrophy.
RiboCore products are supplied strictly for laboratory and in-vitro research. This page is educational and should not be read as medical advice, a diagnosis, or a recommendation for human use.
What the trial found
These are the primary findings as reported by the investigators. This is a summary, not an endorsement of off-label use.
- Tesamorelin reduced trunk fat by 15.2% and visceral adipose tissue significantly compared to placebo over 26 weeks in HIV patients with lipodystrophy.
Tesamorelin reduced belly fat by about 15% in HIV patients who had abnormal fat accumulation — and it improved their cholesterol at the same time.
- Unlike exogenous growth hormone, tesamorelin stimulates the pituitary to produce GH physiologically, preserving the body’s natural feedback mechanisms.
Unlike injecting growth hormone directly (which floods your system), tesamorelin nudges your own pituitary gland to release GH in natural pulses, keeping your body’s feedback system intact.
- Improvements in lipid profiles (triglycerides, cholesterol ratios) accompanied the fat reduction.
The fat it targeted was visceral fat — the dangerous kind that wraps around your organs and drives heart disease and diabetes risk — not just the fat under your skin.
- Tesamorelin received FDA approval in 2010 as Egrifta, making it the only growth hormone-releasing factor approved for clinical use in the United States.
Tesamorelin is the only growth hormone-releasing peptide that made it all the way through FDA approval. It’s been a prescription drug (Egrifta) since 2010.
Evidence snapshot
Tesamorelin’s FDA approval provides the strongest regulatory validation for the growth hormone secretagogue class, demonstrating that peptide-mediated GH release can achieve clinically meaningful outcomes.
GHRH analog preserves physiological GH pulsatility
Unlike direct GH injection (which bypasses the hypothalamic-pituitary axis), tesamorelin stimulates the pituitary gland to release growth hormone in a physiological pulsatile pattern. This preserves negative feedback and reduces risk of supraphysiological levels.
Instead of flooding your body with synthetic growth hormone, tesamorelin asks your brain to release your own GH in normal pulses. Your body’s built-in safety checks stay active.
Visceral fat reduction was selective
Tesamorelin preferentially reduced visceral (organ-surrounding) fat rather than subcutaneous fat. Visceral adipose tissue is metabolically more active and more strongly associated with cardiovascular and metabolic disease risk.
Tesamorelin specifically targets the deep belly fat that wraps around your organs — the kind that drives diabetes and heart disease. It’s not just about looking thinner; it’s about removing metabolically dangerous fat.
Lipid improvements accompanied fat reduction
Triglyceride levels decreased and cholesterol ratios improved, suggesting the visceral fat reduction translates to meaningful metabolic improvement beyond body composition changes.
When the visceral fat went down, triglycerides and cholesterol ratios improved too. The fat loss created a cascade of metabolic improvements beyond just body composition.
Claim review
A useful way to read health content is to grade each major claim independently instead of accepting the whole narrative as a package.
“Growth hormone secretagogues are safer than GH injections.”
Secretagogues that work through the GHRH axis preserve physiological pulsatility and negative feedback, theoretically reducing risk of supraphysiological GH exposure. Tesamorelin’s safety profile supports this.
The logic is sound — stimulating your own pituitary preserves natural feedback and pulsing. Tesamorelin’s safety record supports this. But it’s one drug; you can’t generalize to every secretagogue.
“Tesamorelin is an anti-aging drug.”
Tesamorelin is approved for a specific clinical indication (HIV lipodystrophy). While GH decline contributes to age-related body composition changes, tesamorelin has not been studied or approved for anti-aging purposes.
It targets visceral fat and growth hormone decline, both of which worsen with age. But it’s approved for a specific HIV condition, not for aging. No one has run an anti-aging trial with it.
“All GH secretagogues work the same way.”
GH secretagogues act through different receptors: GHRH analogs (tesamorelin, CJC-1295) stimulate the GHRH receptor, while ghrelin mimetics (ipamorelin, MK-677) stimulate the GHS receptor. These have overlapping but distinct profiles.
They don’t. GHRH analogs (tesamorelin, CJC-1295) and ghrelin mimetics (ipamorelin, MK-677) hit different receptors with different effects. Lumping them together is pharmacologically wrong.
Important considerations
- Tesamorelin is approved specifically for HIV-associated lipodystrophy. Off-label use for body composition in non-HIV populations lacks the same level of evidence.
Tesamorelin was tested and approved for HIV lipodystrophy specifically. Using it for general body composition without HIV isn’t backed by the same quality of evidence.
- Growth hormone elevation carries theoretical risks including insulin resistance, fluid retention, and joint pain.
Growth hormone elevation isn’t free of side effects. It can cause insulin resistance, fluid retention, joint pain, and potentially worsen blood sugar control.
- The distinction between GHRH receptor agonists and ghrelin receptor agonists matters pharmacologically and should not be conflated.
GHRH analogs and ghrelin mimetics work through completely different receptors. Saying “growth hormone peptides are all the same” is like saying all blood pressure drugs are identical.
- FDA approval of tesamorelin does not constitute endorsement of other GH secretagogue peptides that have not completed regulatory review.
Just because tesamorelin got FDA approval doesn’t mean other GH peptides (CJC-1295, ipamorelin, MK-677) are safe or effective. Each needs its own evidence.
Research questions worth tracking
- Can tesamorelin or similar GHRH analogs benefit age-related sarcopenia and visceral adiposity in non-HIV populations?
- How does the GH response to tesamorelin change with aging, given age-related pituitary decline?
- What is the long-term metabolic safety profile of sustained GHRH analog treatment beyond the approved indication?
- How do combined GHRH/ghrelin receptor approaches (e.g., CJC-1295 + ipamorelin) compare to single-receptor strategies?
Primary sources
These references anchor the claims in this brief to peer-reviewed literature and authoritative guidance.
Research-use note
Nothing on this page should be used to diagnose, treat, or self-manage any medical condition. If a reader needs clinical guidance, the right next step is a licensed clinician and guideline-based care, not a research brief or a product listing.